• Markets
    • icon
  • Companies
MXC · ASX

MGC Pharmaceuticals Ltd. (ASX:MXC)

AU$0.68

 -0.02 (-2.878%)
ASX:Live
28/11/2023 04:10:31 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

MXC Overview

MXC Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About MXC

Website

MGC Pharmaceuticals Ltd.

Telephone

61.8.6382.3390

Address

1202 Hay Street Perth, Western Australia (WA) 6005

Description

MGC Pharmaceuticals Ltd. engages in the production of medical marijuana. Its Endocannabinoid system covers all cells and nerves; it is the messenger of information flowing between immune system and the central nervous system. The company was founded by Roby Zomer on October 21, 2005 and is headquartered in Perth, Australia.

MXC Price Chart

Key Stats

Market Cap

AU$3.12M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.41 - 14.0

Trade Value (12mth)

AU$4,707.00

1 week

-0.71%

1 month

-30.5%

YTD

-94.21%

1 year

-95.04%

All time high

4950

Key Fundamentals

EPS 3 yr Growth

50400.000%

EBITDA Margin

-435.20%

Operating Cashflow

-$12m

Free Cash Flow Return

%

ROIC

%

Interest Coverage

-57.30

Quick Ratio

0.10

Other Data

Shares on Issue (Fully Dilluted)

3m

HALO Sector

Healthcare

Next Company Report Date

28-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

MXC Announcements

Latest Announcements

Date Announcements

31 October 23

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 18

Annual Report 2018

×

Annual Report 2018

31 May 23

First CannEpil Delivered to UK Patients

×

First CannEpil Delivered to UK Patients

31 July 23

MGC receives permission for first import of Psilocybin

×

MGC receives permission for first import of Psilocybin

31 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 23

Preliminary Final Report

×

Preliminary Final Report

30 October 23

Trading Halt

×

Trading Halt

30 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 October 08

Annual Report to shareholders

×

Annual Report to shareholders

30 October 07

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

30 November 21

Trading Halt

×

Trading Halt

30 November 15

Erin Resources Limited - Results of Annual General Meeting (ERI-AU)

×

Erin Resources Limited - Results of Annual General Meeting (ERI-AU)

30 November 10

Results of Annual General Meeting (HEA-AU)

×

Results of Annual General Meeting (HEA-AU)

30 May 23

Distribution of General Meeting Documents - Notice of Access

×

Distribution of General Meeting Documents - Notice of Access

30 May 23

Notice of General Meeting/Proxy Form

×

Notice of General Meeting/Proxy Form

30 May 23

Corporate Update - Board and UK Adviser Changes

×

Corporate Update - Board and UK Adviser Changes

30 March 23

Results of Meeting

×

Results of Meeting

30 June 23

Company Update

×

Company Update

30 June 23

Details of Company Address

×

Details of Company Address

30 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

30 August 23

Share Purchase Plan Closed

×

Share Purchase Plan Closed

29 September 23

Annual Report to shareholders

×

Annual Report to shareholders

29 September 23

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

29 October 19

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 October 10

Notice of Annual General Meeting/Proxy Form (HEA-AU)

×

Notice of Annual General Meeting/Proxy Form (HEA-AU)

29 November 19

Results of Annual General Meeting

×

Results of Annual General Meeting

29 November 16

Results of Annual General Meeting

×

Results of Annual General Meeting

MXC Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.01 -0.01 -7.07 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.01 -0.01 -7.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock 40.7 4.8 -89,393.7 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.00 -0.01 -4.19 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.01 -0.01 -4.13 Lock Lock Lock
     Growth % Lock Lock Lock Lock 45.1 -41.6 -80,953.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -21.7 -36.2 -82.6 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.01 0.00 -2.21 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.00 0.00 -2.21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 48.4 -66.3 -224,046.5 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 1,906 2,566 3 Lock Lock Lock
Basic m Lock Lock Lock Lock 1,906 2,566 3 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 3 5 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock 44.1 57.9 -28.4 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 11 14 16 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 1 2 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock 340.3 112.1 -55.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock 24.6 33.0 20.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 75 67 79 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -10 -12 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 14.9 -29.7 -17.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -321.7 -264.1 -435.2 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 0 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -10 -13 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 12.9 -25.5 -20.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -343.2 -272.7 -457.4 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -16 -21 -21 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -1 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -16 -20 -21 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.0 -28.2 -2.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -529.7 -430.0 -614.7 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -12 -12 -12 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 3 3 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -1 1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 17 10 10 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -15 -15 -12 Lock Lock Lock
     Growth % Lock Lock Lock Lock -40.3 3.0 18.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -5.1 -3.1 -3.6 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 5 2 0 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 24 19 10 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 2 2 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock 1 2 10 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 10 13 18 Lock Lock Lock
Equity $m Lock Lock Lock Lock 14 6 -7 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 16 8 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 215.3 -49.9 -189.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -65.5 -109.6 -208.6 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -114.7 -348.6 281.3 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -51.8 -87.9 -275.3 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -101.7 -173.8 -5,246.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -76.8 -103.8 -3,019.6 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock -26.1 -59.5 -57.3 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock -0.1 -0.2 -0.6 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock 4.2 42.2 -128.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 1.5 0.8 0.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 1.4 0.6 0.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 57.3 29.2 9.5 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -195.6 -157.8 -89.9 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 1.3 2.2 2.7 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 2.6 2.3 1.7 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.9 N/A 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 40.8 53.3 64.5 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.3 0.3 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.3 0.3 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -547.6 -438.9 -623.8 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -67.7 -111.9 -211.7 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -65.5 -109.6 -208.6 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.8 3.2 -1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -114.7 -348.6 281.3 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -114.7 -348.6 281.3 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 140.9 156.0 217.2 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 286.1 165.3 133.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 427.1 321.3 350.2 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 197.4 165.3 388.3 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 229.6 156.0 -38.1 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

MXC Shortsell

Frequently Asked Questions

The current share price of MGC Pharmaceuticals Ltd. (MXC:ASX) is AU$0.68.
The 52-week high share price for MGC Pharmaceuticals Ltd. (MXC:ASX) is AU$14.00.
The 52-week low share price for MGC Pharmaceuticals Ltd. (MXC:ASX)? is AU$0.41.
MGC Pharmaceuticals Ltd. (MXC:ASX) does not pay a dividend.
MGC Pharmaceuticals Ltd. (MXC:ASX) does not pay a dividend.
MGC Pharmaceuticals Ltd. (MXC:ASX) has a franking level of 0%.
MGC Pharmaceuticals Ltd. (MXC:ASX) is classified in the Healthcare.
The current P/E ratio for MGC Pharmaceuticals Ltd. (MXC:ASX) is .
halo-logo-inverted-rgb@72ppi-1
Login
Products
Company
Important

Get the latest insights and hot tips delivered right to your inbox

Apple Store
Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.